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collaboratively developing a research proposal
Fiona Poland1, Sarah Mapes2, Hilary Pinnock3, Cornelius Katona4, Susanne Sorensen5, Chris Fox6
and Ian D Maidment7*Abstract
Background: The need for carers to manage medication-related problems for people with dementia living in the
community raises dilemmas, which can be identified by carers and people with dementia as key issues for
developing carer-relevant research projects.
A research planning Public Patient Involvement (PPI) workshop using adapted focus group methodology was held
at the Alzheimer’s Society’s national office, involving carers of people with dementia who were current members of
the Alzheimer’s Society Research Network (ASRN) in dialogue with health professionals aimed to identify key issues in
relation to medication management in dementia from the carer viewpoint. The group was facilitated by a specialist
mental health pharmacist, using a topic guide developed systematically with carers, health professionals and
researchers. Audio-recordings and field notes were made at the time and were transcribed and analysed thematically.
The participants included nine carers in addition to academics, clinicians, and staff from DeNDRoN (Dementias and
Neurodegenerative Diseases Research Network) and the Alzheimer’s Society.
Findings: Significant themes, for carers, which emerged from the workshop were related to: (1) medication usage
and administration practicalities, (2) communication barriers and facilitators, (3) bearing and sharing responsibility and
(4) weighing up medication risks and benefits. These can form the basis for more in-depth qualitative research
involving a broader, more diverse sample.
Discussion: The supported discussion enabled carer voices and perspectives to be expressed and to be linked to the
process of identifying problems in medications management as directly experienced by carers. This was used to inform
an agenda for research proposals which would be meaningful for carers and people with dementia.
Keywords: Dementia, Service user engagement, Medicines management, Family carersBackground
The prevalence of dementia is growing rapidly; in the
UK 700,000 people currently live with dementia and this
is predicted to double over the next 30 years [1,2]. As the
condition progresses, people with dementia are increasingly
less able to care for themselves making the role of family
carers especially important for supporting them to continue
to live in the community. People with dementia may re-
ceive many different medicines, both for the dementia* Correspondence: i.maidment@aston.ac.uk
7Pharmacy, Medicines and Devices in Ageing Cluster Lead, Aston Research
Centre for Healthy Ageing (ARCHA), School of Life and Health Sciences, Aston
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Dedication waiver (http://creativecommons.or
unless otherwise stated.and for other health problems [3]. However, medications
can cause adverse health events [4]. Despite people with de-
mentia being at particular risk of developing medication-
related problems, little is known about the specific issues
which relate to their medication management [5,6].
Building shared understandings is important for discov-
ering what medication management issues may be seen
as most relevant research topics for people with demen-
tia and their carers living in the community.
Since the 1980s, there has been increasing international
emphasis on involving the general public and service
users in various aspects of healthcare [7-10]. Depart-
ment of Health strategy documents have identified theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of carer workshop participants
Number of carers from the ASRN 9
Number of female carers 8
Ethnicity White British (n = 9)
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aspects of research [11]. Both the defining of topic and tar-
get population as well as appropriate and acceptable design
approaches provide key opportunities for such involvement
[12]. In dementia, as carers have a central role in medi-
cation management, they would need to be involved in
designing any study. We therefore involved carers in iden-
tifying priorities for, and discussing the feasibility of a re-
search project, focusing on the real-world experiences and
needs of people with dementia and their carers.
The Alzheimer’s Society set up a volunteer group in 2000
to advise on its research funding programme, to ensure its
greater relevance to people with dementia and their carers.
Roles for volunteers include setting research priorities and
scoring research applications for likely importance of out-
come [13]. By 2011, the network had become central to
Alzheimer’s Society’s research management, renamed
Alzheimer’s Society Research Network (ASRN used for
consistency in this paper) with 180 active members. Mem-
bership is restricted to people with dementia, carers and
former carers for people with dementia. To promote the
development of higher quality research projects in areas
prioritised by the network, Alzheimer’s Society colla-
borated with the National Institute for Health Research
(NIHR) Dementias and NeuroDegenerative Diseases
Research Network (DeNDRoN) to organise an intensive
workshop using modified focus group methods. Focus
groups are frequently used in exploratory research,
when little is known about the topic [14] and the group
format may also facilitate the discussion of difficult and
challenging experiences [15].
The developmental workshop on Medication Manage-
ment in Dementia described here was initially proposed at
a DeNDRoN Dementia Clinical Studies Group meeting.
The lay members clearly articulated the particular import-
ance of examining practice and communications around
managing medication for the person with dementia in-
cluding the practical problems involved. The workshop
aimed to encourage a direct pharmacist-researcher-carer
consideration of the dilemmas represented by carer mem-
bers’ attempts to deal with medication issues, resonating
with previous pharmacist investigations on the complex-
ities raised [16]. The paper aims primarily to describe the
PPI process which was intended to inform and validate the
development of a future research proposal which could be
well-informed by carers' perspectives.
Method
Workshop aim
A research planning PPI workshop using an adapted focus
group methodology was held. The aim of the workshop
was to develop an understanding of issues for a potential
research study through identifying the carer’s views gained
from experiences of medication management in dementia.Carer priorities, perceived benefits and side-effects of
medication, issues for adherence, prescribing and dispens-
ing, medication reviews, communication with healthcare
professionals and any relevant ethical issues were ex-
plored. Understandings developed were then used to in-
form the design of a research proposal to develop systems
to improve medication management for people with de-
mentia. Reported thematic outcomes from workshop
discussions were treated as part of this development
process, posing questions to be explored in future re-
search, but not being claimed to be established research
findings. As this was not in itself a research project, it is
therefore not reported using Consolidated Criteria for
Reporting Qualitative Research (COREC) standards.
Setting up and running the workshop group
In February 2011 an extended, supported workshop (two
sessions of two hours each) was conducted with carers or
ex-carers of people with dementia from ASRN who had
received training about research processes and method-
ologies. Potential participants, who were members of the
ASRN with experience of managing medication, were
identified in two ways. First, we purposively identified
ASRN members, who might have something specific to
contribute to the theme based on their particular circum-
stances and previous discussions with them. Second, the
whole membership was informed about the planned
group in the general monthly mailing and those interested
in participating were invited to contact the Alzheimer’s
Society Research Office. Any members who contacted the
Research Office were informed about the aims and objec-
tives of the group. Based on these discussions, potential
participants, purposively selected on the basis of specific
criteria namely experience of medication management in
dementia either as a carer or a person with dementia, were
invited to attend the group (see Table 1 for details of the
purposive sample of ASRN members who attended).
The group was facilitated by the mental health
pharmacist (IM) supported by the qualitative re-
searcher (FP) and the GP (HP); the Head of Research at
Alzheimer’s Society (SS), the DeNDRoN Patient Public In-
volvement Officer, two administrators from DeNDRoN
and a community pharmacist (SM) were also present. A
topic guide was developed with the health professionals,
researchers and the carers to ensure the systemic inclu-
sion of carer voices (see Appendix 1).
An outline of the proposed exploratory workshop and
the overall aim was sent to the local NHS Research Ethics
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concluded that ethical approval was not required. The
focus group discussion was audio-recorded by a DeN-
DRoN administrative team member, transcribed by an
experienced transcriber and supplemented by observation
field notes by FP and SM. Participants gave consent for
the recording by completing the Alzheimers Society’s
Audio Consent Form.
Analysis
The approach to analysis was informed by the need to
ensure that the detailed perspectives participants were
bringing to this PPI process were systematically identi-
fied and that the PPI process itself could be fully appre-
ciated. A combination of thematic and narrative analysis
itself was therefore used.
Thematic analysis was used to derive meaning units
and themes from the transcripts, to summarise key fea-
tures of the data, contextualising these within the wider
data set [17]. The transcripts were analysed by initial
codes developed by SM and FP; SM and FP initially inde-
pendently coded the transcripts and then jointly discussed
how they should be used to further develop themes.
The thematic analysts met repeatedly to review and
agree emergent themes and to check that all relevant
themes had been identified. The overall themes were vali-
dated with a third member of the team (IM) before being
circulated for further review and agreement to all authors.
Any differences were discussed with reference to the
whole dataset. An element of narrative analysis was also
used to demonstrate how themes were developed through
the group’s conversation, again locating individual contri-
butions within the whole dataset. This meant indicating
those points which were firmly endorsed by a majority of
carers, noting that some voices were stronger over the day
and closely attending to and comparing the contributions
of the less vocal.
Findings
Four key themes that reflected the issues raised at the
DeNDRoN Dementia Clinical Studies Group meeting by
carers and prompted the convening of the workshop,
were identified:
 Medication use and administration practicalities
 Communication barriers and facilitators
 Bearing and sharing responsibility
 Weighing up medication risks and benefits
1. Medication Use and Administration practicalities
The group opened with a prepared account of one
carer’s difficulties with medication for constipation, in-
cluding a demonstration of how quickly the laxative
Fybogel® sets in the glass; much too quickly to beingested by a person with dementia. This brought a con-
sistent response from carers corroborating and elaborat-
ing the account. A sustained focus was brought to bear
on the many practical implications of dealing with the
appropriate use of medication for something that
might be considered as a ‘minor’ problem (constipa-
tion) but which could entail severe emotional and
physical distress for both person with dementia and
carer:
P3 (Carer) I…never talked about (it)…. it developed to
such a point when my mother was actually packed
with faeces….and it didn’t matter what I gave her in
terms of what they tell you in the fact sheets.
She related her own shock, shared by her listeners, of
being abruptly told by a visiting nurse to deal with the
unresolved problems by manually evacuating her
mother’s bowels. She felt this contradicted many aspects
of their previously shared relationship. This highlighted
a particular and repeated feature of carers’ accounts of
practical issues in medications management: the marked
emotional weight such issues and corresponding re-
sponses from health professionals often carried for
them.
Other carers reinforced their sense of despair in trying
to communicate medication-related dilemmas:
P7 (Carer): I would say to them, say no if you can’t do
this, but I am desperate.
The sensed lack of practical support from health and
social care teams in dealing with medications issues was
often stark. One carer (P6) with lengthy experience her-
self in social care reported, that her careful instructions
to paid carers were ignored leaving her “so bloody
annoyed”.
Several carers in the group defined professionals as ne-
cessarily removed from the practical consequences they
dealt with at close quarters, as P2 (Carer) observed:
Don’t forget that the clinician and pharmacist can
have little or no understanding of the practicalities.
For the experienced professionals in the group such
emotion linked discussions made it very apparent how
distant they were from the practicalities and realities of
carers and people they cared for. P15 (Pharmacist re-
searcher) described himself as “shocked by seeing and
hearing this” and, never having seen how Fybogel® was
made up, said that it “really looks revolting”.
Thus an apparently trivial and widely-used medication,
could be seen to raise a host of unforeseen practical is-
sues when having to be negotiated by family carers of
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functioning led to very different needs to be considered.
Carers described how more visible signs and symp-
toms were easier to look out for and helpful in explain-
ing to someone with dementia, whose cooperation they
needed to gain, by saying:
P3 (Carer) this is to make them (your ankles) less puffy
so there’s something very visible that she (person with
dementia) could see…..but for other medications it’s
more difficult to explain why they need to take it.
These discussions led to concerns about many other
types of medication, including those relating to pain re-
lief, hypertension, osteoporosis, diabetes and eye prob-
lems. Each could be seen to have particular requirements
for how and who should administer these as P12 (Carer)
related:
My mother was living alone when she developed the
signs and symptoms……I started to be concerned
about the prescriptions that she was getting for her eye
drops because I knew they had to be administered
properly, but who would know?
This raised the issue of whether the carer or the per-
son with dementia controls use of medication in prac-
tice, and, relatedly, how the carer can decide whether
the person with dementia can no longer safely adminis-
ter medication. P2 (Carer) described subsequent chal-
lenges as “a nightmare” complicated by the unfamiliar
terminology used by health professionals and ambiguity
about responsibility for monitoring their use:
who monitors as required (PRN medication)…
Sometimes you get an agency nurse sent into just to do
the drug round or a relative who do you ask whether
they think it’s PRN and that was one of the things that
was caused a lot of my husband’s distress…….he
actually got it everyday. That’s not PRN so there’s a lot
of ambiguity.
The examples cited here show graphically how the
medications management practicalities raised for carers
were not specific to drugs for dementia. However, man-
aging the medications for other pathologies was com-
plicated by the need to take into account the changed
experience and capabilities of the person with demen-
tia, which can transform the medications-related work
that may have fitted almost unnoticed into everyday
routines of people when they were not living with de-
mentia. Striking in these accounts, and readily recog-
nisable by the health professionals here, was that such
practicalities were not experienced as neutral for carers,often causing high levels of embarrassment in which
their identities and expectations as family members
were undermined. All of this created uncertainty and
further questions about how they might communicate
within the family and with health professionals to gain use-
ful knowledge and regain a sense of control. Barriers and
facilitators to such communication are explored in the
following theme.
2. Communication barriers and facilitators
Changes in the nature and quality of communication
with health professionals could be experienced as pivotal
to carers’ ability to engage with medication issues ini-
tially appearing insuperable:
P3 (Carer) After months I got it absolutely perfectly
balanced with a lot of help from the District Nurse….
she went way beyond what she should have done….I
will be eternally grateful to her …
Here, building a supportive relationship with a clinician
was seen as an important facilitator to communication, as
another carer’s (P8) later comments also illustrate:
the most important thing…..…was the fact that she
had direct access to this District Nurse which made an
absolute difference if you have an access point and you
have good communication.
Complex issues of embarrassment about disclosure of
their relative’s loss of dignity and/or of their own per-
ceived lack of knowledge could entail powerful barriers
to communication:
P5 (Alz Soc Researcher) it’s the embarrassment factor
that …we might actually need something for
constipation so should there be prompts.
P3 (carer) thought that men, who were carers, found it
especially difficult to discuss personal care issues:
Often men cover up for their wives……
Again a sense of shame and betrayal was graphically
demonstrated when carers spelt out what care problems
they were dealing with; articulated by some carers as
betraying their relation’s trust in them to preserve
confidentiality:
P8 (Carer) it was my husband; I felt almost unfaithful
exposing him.
However, confidentiality issues could also be caused
by professional codes which focused on the person with
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leaving carers feeling in the dark and unsupported:
P11 (Carer) The GP was trying to keep private
confidential information, but it was extremely
frustrating for us wanting to get some support.
Carer-health professional discussion became particu-
larly animated when elaborating the need for and possi-
bility of medications advice which carers could keep
ready to hand, perhaps as a checklist, listing key infor-
mation, in lay terms, on medications (their effects, side
effects and usage instructions etc). All carer participants
expressed active agreement with this as a means to be
informed and communicated with about medications, as
P2 (Carer) suggested:
Some kind of check list…our own simplified version of the
BNF (British National Formulary; a textbook designed
for clinicians with guidance on medicines management).
However, the issue of indicative labelling on medica-
tions packaging demonstrated how barriers to providing
simple information or instructions might arise. Health
professional participants pointed out that a drug might
have more than one use:
P10 (Pharmacist) quite often there are multiple uses
for a single drug.
So it would not always be immediately obvious what
labelling would be appropriate. Neither was it necessarily
clear when and how such information might need to be
given as some professionals and lay members had diver-
gent views on whether such information-giving would
improve patient care:
P14 (GP) We don’t know yet whether it works because
I’m afraid there's no evidence.
P8 (Carer) The pharmacists are saying it would be helpful.
P5 (AS staff) said that previous discussions had suggested
the potential of a prompt list to encourage people to ask
the questions that “perhaps wouldn’t come by themselves”
and went on to ask how carers and professionals might use
or accept such questions. Carers and professionals dis-
cussed at length where simplifying such information-
seeking and information-giving, particularly for the most
common side effects could ease decision-making.
P8 (Carer) Please, a simple prompt list.
Carers offered highly-specific suggestions about how
such checklists might be used in nursing homes to assistmedication management, for example stuck to the “drug
trolley” and also to flag up when action might be needed:
P2 (Carer) before you give the drugs if something
occurs ask the GP or go back to the pharmacist …
The impact of the quality of the communication with
professionals on carers’ decision-making responsibilities
is explored next.
3. Bearing and sharing responsibility
Another strong theme was the carers’ detailed consider-
ation of medication management as bringing a heavy
burden of responsibilities, which they felt might be eased
through sharing it with appropriate health professionals.
However, as seen in the first two themes, this could not
be counted on.
The nature of that burden was closely linked to carers’
anxiety about whether they could care well enough:
P8 (Carer) I really do wish you wouldn’t ask me how
I’m coping because the word coping implies that if I’m
not, it’s my fault.
They also talked about their additional sense of failed
responsibility if they could not manage medications by
noticing and responding to changes in the health of the
person they care for:
P2 (Carer) it would be neglect and carelessness to
carry on giving laxatives when they have diarrhoea.
As well as the requirement to “read” the health care
and medication needs of the person they care for, the
carer also needed to translate experts’ advice:
P13 (Carer) the carer….interprets the advice of the experts.
As individuals’ dementia progressed, this increased such
difficulties for carers in communicating with them to as-
certain their needs, again risking “letting them down”:
P12 (Carer) She had no communication except for the
tearful eyes and I thought god (I have) really let you down.
Such comments indicate how, especially in relation to
medication, carers cannot be sure they are adequately
informed to fulfil such responsibilities. They went on to
consider how having clearer information could help
them fulfil their responsibilities:
P2 (Carer) One of the things also that us and paid
staff need better to do is powers of observation, it’s not
just a checklist, and notice if somebody’s got a rash.
Poland et al. BMC Research Notes 2014, 7:463 Page 6 of 10
http://www.biomedcentral.com/1756-0500/7/463Carers also saw it as part of their role to help empower
people with dementia in relation to medication including
seeking ways to support the person they cared for retain
control of medications:
P12 (Carer) I think she felt a loss of independence
when the dementia hit. But not only that but as
soon as her own control over her own medication,
that she was so used to, was taken out of her
hands….so it’s giving the autonomy to the patient as
far as possible.
The monitored dose medication system, designed to
support administration and usage of medication by
carers, again attracted opposing views from carers,
who found them useful and health care professionals
who saw them as “systems abused by care homes”
(P15, Pharmacist researcher) and “desperately frustrat-
ing” (P14, GP).
Where carers could trust the quality and commitment
of their support team they were more likely to share
such responsibilities with them. However, a striking ob-
servation, especially in this pharmacist-facilitated discus-
sion about potentially-helpful professionals, was carers’
general lack of awareness of pharmacists despite recent
efforts to raise their profile:
P10 (Pharmacist) We have an "ask your pharmacist
week" don’t we, but we’re obviously not promoting
ourselves enough.
Overall, this theme helped highlight how uncer-
tainty and poor communication added to carers’ diffi-
culty in sensing how to share their heavy burden of
responsibility for difficult medications decisions.
4. Weighing up medication risks and benefits
As the discussion developed, carers expanded on the
burden of responsibility they carried in having to make
decisions about whether benefits of their relative taking
medications outweighed the risks, experiencing guilt and
self-remonstration when they later felt their decision
had led to ill-health:
P3 (Carer) I carried on giving my mother her diuretics
actually she was dehydrated. Neither the doctor nor I
thought and I thought afterwards what an idiot I
should have made that connection myself.
This instance exemplified carers' difficulties in weigh-
ing up risks with benefits in the absence of access to ex-
pert knowledge about medications.
Some aspects of the dementia care situation, as with
challenging behaviour, make it harder to balance thebenefits of medication with harms to reputation and
moral sense as well as health:
P9 (Carer) what happens if you’ve got someone who is
a violent patient…and the family have refused to give
permission for the person to have drugs.
Several carers mentioned the potential stigma of being
known to use anti-psychotics even when their experi-
ence suggested that they might be appropriate:
P8 (Carer) My husband would have been humiliated….
if he had recognised his aggression and his nastiness
with people so anti-psychotics have got a place and…..
the bad press that it gets makes it very difficult.
In such ways, carers’ accounts underlined their acute
awareness of needing to balance the harms (including
shortening life) as well as benefits of medications:
P2 (Carer) It’s length of life versus quality of life and that’s
something that we as carers we’re very loathe to face.
This may resonate with recently-emerging ideas about
time to benefit, increasingly considered in end-of-life care,
where a medication may be dispreferred if it takes longer
to produce benefits than the predicted life expectancy,
suggesting that dementia-specific evidence may to help
ease carers’ concerns [18].
While the potential harms from drugs readily raised
fears for carers, there was no corresponding sense in the
experiences shared within this group that it was easier
to decide on when it might be beneficial rather than
harmful to stop drugs; although some carers were pre-
pared to face the issue:
P11 (Carer) We stopped giving my mother the calcium
altogether because she’d had a bone scan and it had
been reasonably ok.
Several carers raised, but understandably did not want
to face, the possibility that stopping medication might be
a sign of potentially losing the person they cared for:
P8 (Carer) And I don’t think anyone wants to face it
really
Furthermore, even where the quality of life issues ap-
peared clear in the abstract, carers agreeing to withhold
medication was not readily experienced as right to do:
P3 (Carer) She (a friend’s wife) had chest infection
after chest infection and in the end he talked with the
doctors and they agreed if she had another one
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treat and he rang up after she died and said I don’t
know whether I can live with the guilt of what I’ve
done you know I’ve let her die.
Carers used terms such as “drug cocktail” to connote
random mixtures without individual benefit, or talked of
the “chemical cosh” in damning terms. The administra-
tion of sleep medication was an especially challenging
decision as promoting sleep for both the person they
cared for and allowing the carer more rest, could be seen
as administering unnecessary drugs only in their own in-
terests. As P7 (Carer) recounted:
There’s also the question of whether the carer requests
it or whether this is all unethical. Again it’s because
the only time I had a drug for my mother was when
she wasn’t sleeping and therefore I wasn’t sleeping so
I said she’s going to have something to put her out
at night.
This raises the challenge of directly counterposing the
differing needs of the carer and of the person with de-
mentia, and of who might advocate for the person with
dementia in medications administration. Carers provided
mutually reinforcing examples of the weight of conflict
imposed on them:
P7 (Carer) My father he wandered and if you don’t get
any sleep at all you get ragged
Carers were keen to suggest that the need for medication-
based solutions for behavioural issues might lessen, if a
supportive relationship with a clinician could be estab-
lished. P11 (Carer) went on to underline that having
more support to reduce their isolation (so “bearing and
sharing responsibility”) might reduce the need to con-
sider “drugging:”
I had nights I was dealing with her on my own to begin
with and I was absolutely worn to a frazzle. If
eventually I got the support…you can manage….you
should be caring for these people not drugging them up.
Reflections
This paper has set out an initially carer-led process and
outcomes from facilitating carers of people with demen-
tia to identify and prioritise issues for research relating
to medications use [11,12]. The methods used drew on
carer-professional-academic engagement in a dementia-
specialist clinical study group meeting, planning a focus
group of mainly carers, systematically supported to con-
tribute through a facilitated extended workshop from
which contributions were thematically analysed [17].The workshop provided rich articulation of the process
of developing research. The “thick description” available
in detailed stories from carers’ personal experiences pro-
vided nuanced insights into how they identified challen-
ging emotional, practical, ethical and conceptual issues,
described in context, within mutually supportive dialogue.
These allowed issues for study and design, to be defined
and prioritised. Viewing them holistically helped critically
re-appraise those complex health and social care partner-
ships within which carers needed communication and
support to deal with medications management.
The focus group discussion made clear that managing
medication in dementia is neither trivial nor emotionally
neutral for carers and patients. Furthermore, since this
workshop was conducted a recent narrative review identi-
fied the complexity of the role and the need for further re-
search [19]. The depth and range of emotions expressed
and the variety of specific dilemmas and decision-making
confronted by carers, provided powerful, detailed reasons to
carry out research here and pointed to areas of most rele-
vance. The discussions highlighted the need to understand
why health care professionals might not spend time listen-
ing to patients and carers so as to address their medication-
related difficulties and concerns. As pharmacist participants
noted, while they routinely talk to individuals daily, the
workshop confronted them with effects of different ways of
eliciting carers’ key concerns. This underlined the value of
facilitated discussion for better recognising the day-to-day
practical difficulties in medication management from carers’
perspectives, so as to facilitate more meaningful and con-
structive carer-health professional communication.
Emergent themes identified the need for clear recogni-
tion and sharing of understandings of and communication
around medications, particularly as many medications
which raise relatively few management problems in people
without dementia, confronted dementia carers with a host
of practical, emotional and ethical problems, whose reso-
lution requires further research. There was a lack of
awareness of potential support, particularly of services
available from pharmacies.
This discussion within the workshop also enabled carers
to suggest areas for developing interventions to be tested
such as information checklists to ease administration and
labelling to support carers’ decision making. Carers’ graphic
descriptions of issues which challenged them in managing
medication helped indicate features which would be im-
portant for carers to be recruited to any studies of interven-
tions [12]. Within these discussions, the power of shared
experience was seen to strengthen the case for identifying
as important, specific details to be considered in developing
interventions, perhaps balancing the formal weight given to
more “objectively evidenced” issues [20].
Bringing health professionals into dialogue with carers in
an extended workshop may have brought more perspectives
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ence, understanding and weighting of medications issues.
However, this may also have brought some potential limi-
tations, now examined.
Strengths, limitations and implications for carer involvement
A strength of this examination of the PPI development
process was that the workshop allowed lay carer partici-
pants space and time to discuss issues important to
them, in ways and language comfortable for them, with
peers and Alzheimers Society staff with whom they had
built a long-term relationship. This also helped dementia
researchers and health practitioners to engage in research-
related dialogues with carers and to see how incorporating
carers’ perspectives could enhance the quality and signifi-
cance of research being developed.
The reported thematic outcomes have been treated as
part of this development process, posing questions to be
explored in future research, but not being claimed to be
established research findings. A further strength is the
rigour of analysis applied to the examination of carer
views expressed in this consultative process, unusual for
such exercises. Nonetheless, as this was not a research
project in itself it is therefore not reported to COREC
standards.
A relative limitation might be that the findings are based
on one workshop with a purposive sample within the sam-
pling pool of a single organization albeit with a national
membership. As such they may have wider indicative res-
onance but not generalisability. A further limitation is that
whilst via the Alzheimer’s Society network both carers and
people with dementia were invited to participate only
carers attended the event.
Limitations may also have followed from the event’s
duration. As the day went on and more technical aspects
of medications were discussed, far fewer carers seemed
to have the energy or interest to engage with mostly
health professional-initiated issues. Therefore, only the
earlier parts of the workshop, with which carers were
more fully engaged, were used in reporting thematic de-
velopment. An extended workshop may require more re-
sponsive and reflexive attention to processes to sustain
and empower lay participants’ continued engagement
and ownership of discursive directions, particularly as
the group environment, in addition to being empower-
ing, may inhibit people from discussing certain issues
[15]. Constantly reviewing the process with all partici-
pants and providing more preparation time and facilita-
tor planning would strengthen carer empowerment, to
maximise their potential contribution.
Conclusions
Carers face many challenges in supporting relatives with
dementia as symptoms progress, often alongside multi-morbidities. Family carers are often confronted with dif-
ficulties connected with medications management and
lacking appropriate forms of support. Directly involving
carers in specifying topics that matter to them, can
greatly enhance the relevance and feasibility of research to
develop effective interventions. This paper has highlighted
ways of supporting carers to articulate their experiences in
order to develop meaningful research topics and processes.
A focus group of carers from a “consumer” research
network with facilitated shared discussion of issues
already identified by them as important and with contri-
butions from interested health professionals was seen to
substantially contribute to proposals for researchable
topics. While this allowed a more relaxed, lay-oriented
discussion, it was also seen to place demands on facilita-
tors to constantly review participants’ energies and inter-
ests as discussion progressed. Embedding the workshop
membership and event within longer term processes and
networks for supporting carers’ voices in developing re-
search helped prepare carers to take part in this research
development process on their own terms while building
dementia researchers’ and health practitioners’ experi-
ence of engagement in dialogues to enhance research
development.
The problems faced by carers were richly demonstrated
and their key priorities for developing interventions were
contextualised in their lives and working partnerships with
health professionals. The emotional costs, the commu-
nications gaps and complex ethical decision-making
burdens emerged as issues to be considered as research
topics, and should also inform research approaches to
be adopted for successfully recruiting and engaging
carers and people with dementia in related research.
The workshop highlighted the complexity of developing
interventions to facilitate effective medication manage-
ment while helping scope some priorities as feasible and
desirable for research. The focus group was primarily
set up to ensure that research in medication manage-
ment in dementia can adequately recognise the import-
ance of carers’ roles and responsibilities. The power of
the carers’ contributions was amply demonstrated in the
ground covered, which clearly indicated health profes-
sionals’ major knowledge and practice gaps and that as-
sumptions that medication management practices in
dementia care in the community were working without
problems are false.
Appendix 1
Topic Guide for Workshop - Perspectives of carers on
medication management in dementia
1. Medication in dementia. Overview
– What do you think is involved in managing
medicines?
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How easy are these to arrange? Do risks also have
to be managed? What sorts of responsibilities are
involved? Who takes responsibility?]
2. Is it important for you? If yes, why?
– [Consider] What is the potential impact on the
person with dementia?
– What is the potential impact on the carer e.g. do
you find medication management activities relatively
easy, or stressful?
3. Brainstorming session – flip chart to consider the
important aspects of medication management.
4. Practical aspects of medication management
– How do you encourage compliance/adherence?
– How do you decide whether the person in your
care for is capable of self-administration, or
whether you need to administer the medication?
– How do you decide whether medication,
including as required, is needed?
– Are there any issues regarding
communication with healthcare professionals
including confidentiality issues?
– How easy is it to maintain a continuous supply
of medication for the person you care for?
5. Need for carers to make clinical-type judgements
– How do you identify and manage side-effects in
the person with dementia?
– How do you decide whether treatments for
cognitive impairment and dementia associated
challenging behaviour are working (particularly
bearing in mind fluctuations over the course of
the day)?
– Do you have a role in identifying any mistakes
e.g. checking that the medication details are
correct – particularly for people with dementia
transferred between primary and secondary
health services?
6. Potential interventions to improve medication
management in the population
– What specific problems (or bits of bad practice)
regarding medication management pertaining to
dementia have you ever encountered?
– Can you think of any elements of good practice
relevant to medication for dementia that could
or should be implemented?
– What possible solutions could you think of to
improve medication management in dementia?
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